众生药业(002317) - 2023 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2023 was CNY 588,989,080.49, a decrease of 11.48% compared to the same period last year[17]. - Net profit attributable to shareholders for Q3 2023 was CNY 70,945,398.72, an increase of 52.58% year-on-year[17]. - Net profit excluding non-recurring gains and losses for Q3 2023 was CNY 70,681,973.48, a decrease of 10.88% compared to the same period last year[17]. - The company's basic earnings per share for Q3 2023 was CNY 0.08, an increase of 33.33% year-on-year[17]. - The company's diluted earnings per share for Q3 2023 was also CNY 0.08, reflecting a 33.33% increase compared to the same period last year[17]. - Net profit for the current period was ¥279,214,968.42, compared to ¥246,324,247.33 in the previous period, indicating an increase of approximately 13.3%[57]. - The total profit for the current period was ¥314,360,157.82, compared to ¥285,819,994.76 in the previous period, indicating an increase of approximately 10.0%[57]. - The total comprehensive income for the current period reached ¥282,956,241.04, compared to ¥252,754,966.85 in the previous period, reflecting an increase of about 11.9%[57]. Assets and Liabilities - Total assets as of the end of Q3 2023 reached CNY 6,422,045,265.53, an increase of 11.20% from the end of the previous year[17]. - Total assets increased to CNY 6,422,045,265.53, up from CNY 5,775,284,499.26, reflecting a growth of approximately 11.2%[27]. - The total liabilities decreased to CNY 1,860,322,155.27 from CNY 1,958,820,439.83, indicating a reduction of approximately 5%[27]. - The total non-current liabilities amounted to CNY 925,001,734.09, compared to CNY 850,493,084.87, showing an increase of approximately 8.8%[27]. - The company's equity increased to CNY 4,561,723,110.26, up from CNY 3,816,464,059.43, reflecting a growth of about 19.5%[27]. - The company's equity attributable to shareholders increased to ¥4,379,338,858.24 from ¥3,702,739,955.97, representing a growth of approximately 18.3%[52]. Cash Flow - The cash flow from operating activities for the year-to-date was CNY 55,643,062.22, a decrease of 60.22% compared to the same period last year[17]. - Net cash flow from operating activities decreased by 60.22% to ¥55,643,062.22 from ¥139,886,612.94, primarily due to increased capital usage from early procurement of raw materials[44]. - Net cash flow from investing activities improved by 61.05% to -¥189,399,577.93 from -¥486,289,822.67, influenced by increased bank product redemptions and asset investments[44]. - Net cash flow from financing activities increased by 50.86% to ¥818,959,164.52 from ¥542,865,169.87, due to funds raised from stock issuance and equity financing[44]. - The net increase in cash and cash equivalents was ¥685,620,874.75, a 243.42% increase from ¥199,644,402.14, mainly due to funds raised from stock issuance and equity financing[44]. - Total cash and cash equivalents at the end of the period reached CNY 1,597,855,253.30, up from CNY 1,214,775,616.64 at the end of the previous period[59]. - Cash received from sales of goods and services was CNY 1,775,689,337.03, compared to CNY 1,646,897,464.68 in the previous period, indicating a growth of 7.83%[58]. - Cash paid for purchasing goods and services was CNY 612,126,897.40, an increase from CNY 455,270,664.43 in the previous period[58]. - Cash received from investment income was CNY 18,856,185.80, up from CNY 3,829,816.11 in the previous period, showing a substantial increase[58]. - Cash inflow from financing activities totaled CNY 1,736,408,407.02, significantly higher than CNY 832,446,488.17 in the previous period[59]. - Cash paid for debt repayment was CNY 743,199,480.00, compared to CNY 111,000,000.00 in the previous period, indicating increased debt management[59]. - The company reported a net cash increase of CNY 685,620,874.75 for the current period, compared to CNY 199,644,402.14 in the previous period[59]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 111,545, with the top ten shareholders holding significant stakes[23]. - Zhang Yuchong and Zhang Yuli each hold 10.86% of shares, amounting to 92,640,500 shares each, with substantial pledged shares[23]. Research and Development - The company's intangible assets increased by 71.32% to CNY 446,104,416.53 due to the capitalization of R&D expenditures[21]. - Research and development expenses decreased to ¥81,119,346.81 from ¥88,566,717.23, a reduction of about 8.1%[52]. Financial Performance - Total operating revenue for the current period reached ¥2,071,278,555.78, an increase of approximately 4.0% compared to ¥1,991,202,038.72 in the previous period[52]. - Total operating costs amounted to ¥1,744,613,102.75, up from ¥1,694,656,021.34, reflecting a rise of about 2.9%[52]. - Other comprehensive income after tax for the current period was ¥3,741,272.62, compared to ¥6,430,719.52 in the previous period, a decrease of about 41.5%[57].